和铂医药（上海）有限公司 Harbour BioMed Mediaroom

Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis

The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patient...

2026-10-23 08:02 3023

Nona Biosciences Successfully Develops World's First Language Model Trained on Fully Human Heavy-Chain-Only Antibodies

CAMBRIDGE, Mass., Sept. 16, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology ...

2026-09-16 18:01 2435

Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy

* Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clin...

2026-09-09 19:12 2849

HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study

* The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the...

2026-09-08 20:17 2522

Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed...

2026-08-27 22:09 3077

Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed...

2026-08-27 22:04 6055

Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- Harbour BioMed...

2026-08-18 17:02 2292

Harbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Harbour BioMed ...

2026-08-06 16:10 3379

Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed...

2026-07-27 17:02 5430

Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed...

2026-07-24 08:02 7209

Nona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases

Partnership grants Ignaz Semmelweis Institute access to Nona's H2L2 Harbour Mice ® transgenic mouse ...

2026-07-23 08:55 3288

Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 15, 2026 /PRNewswire/ -- Harbour BioMed...

2026-07-15 18:01 4262

Nona Biosciences Appoints Dr. Peng Wang as Chief Operating Officer to Advance Platform Capabilities and Drive Operational Excellence

CAMBRIDGE, Mass., July 2, 2026 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global...

2026-07-03 09:36 5052

Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases

CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology co...

2026-07-02 08:05 3923

Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 28, 2026 /PRNewswire/ -- Harbour BioMed...

2026-06-29 09:27 2729

Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven Complex Biologics R&D

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 15, 2026 /PRNewswire/ -- Harbour BioMed...

2026-06-15 20:10 7507

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

* The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an ...

2026-06-15 08:01 6854

Latest News